GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Other Operating Expense

Cellectis (Cellectis) Other Operating Expense : $-4.30 Mil (TTM As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Cellectis Other Operating Expense?

Cellectis's Other Operating Expense for the three months ended in Sep. 2023 was $0.19 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2023 was $-4.30 Mil.

Cellectis's quarterly Other Operating Expense declined from Mar. 2023 ($-0.67 Mil) to Jun. 2023 ($-1.03 Mil) but then increased from Jun. 2023 ($-1.03 Mil) to Sep. 2023 ($0.19 Mil).

Cellectis's annual Other Operating Expense increased from Dec. 2020 ($1.60 Mil) to Dec. 2021 ($1.70 Mil) but then declined from Dec. 2021 ($1.70 Mil) to Dec. 2022 ($-1.22 Mil).


Cellectis Other Operating Expense Historical Data

The historical data trend for Cellectis's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Other Operating Expense Chart

Cellectis Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.95 -7.71 1.60 1.70 -1.22

Cellectis Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.87 -2.80 -0.67 -1.03 0.19

Cellectis Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cellectis Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Cellectis's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectis (Cellectis) Business Description

Traded in Other Exchanges
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Cellectis (Cellectis) Headlines

From GuruFocus

Cellectis Announces Pricing of Follow-On Offering

By Stock market mentor Stock market mentor 02-03-2023